RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
Recruiting · NCT06328777 · Registry updated 2026-08-17Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis | Skin and Connective Tissue Diseases, autoimmune disease, connective tissue disorder, diffuse scleroderma, immune system disorder, interstitial lung disease, lung disorder, respiratory system disorder, scleroderma, skin disorder, systemic sclerosis | Recruiting | Phase 2 / Phase 3 | 2026-08-17 | NCT06328777 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Cabaletta Bio | 5 |
10 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Columbia University Irving Medical Center | New York | United States | 234 |
| Duke University | Durham | United States | 160 |
| Mayo Clinic Florida | Jacksonville | United States | 1 |
| Mayo Clinic Rochester | Rochester | United States | 133 |
| Northwestern Memorial Hospital | Chicago | United States | 129 |
| The University of Chicago Medical Center | Chicago | United States | 33 |
| University of Kansas Medical Center | Kansas City | United States | 240 |
| University of Michigan | Ann Arbor | United States | 538 |
| University of Rochester | Rochester | United States | 360 |
| Yale University | New Haven | United States | 29 |